3 results
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Primary objectiveThe objective of this study is to demonstrate the 12 month stability of cTnT in native serum, Li-heparin plasma and K2-EDTA plasma samples at -20 ± 5 °C, > 4 hours at 15 to 25 °C, > 24 hours at 2 to 8°C and > 12…
The main objective of this study is to investigate whether quality of life can be improved by personalised and timed guidance, and/or use of the peer-support platform; as provided by a patient-centred mobile application.